Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
2024年2月20日 - 10:15PM
ビジネスワイヤ(英語)
– Immunome entered into a definitive asset
purchase agreement with Ayala to acquire AL102 earlier this month
–
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated
to developing first-in-class and best-in-class targeted cancer
therapies, today recognized the announcement by Ayala
Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology
company, that patient enrollment has been completed in the Phase 3
RINGSIDE study evaluating AL102 in desmoid tumors.
Earlier this month, Immunome announced that it entered into a
definitive asset purchase agreement with Ayala to acquire AL102 and
related drug candidate AL101. Completion of the transaction remains
subject to customary closing conditions.
“We are pleased with the progress of the RINGSIDE trial,” said
Bob Lechleider, M.D., Chief Medical Officer of Immunome. “The
robust enrollment of the Phase 3 portion affirms our excitement for
the potential of AL102. We are also encouraged by the rapidity and
depth of the tumor responses observed in Phase 2. We look forward
to closing the purchase of AL102 later this quarter or early in the
second quarter.”
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing
first-in-class and best-in-class targeted cancer therapies. Our
portfolio pursues each target with a modality appropriate to its
biology, including immunotherapies, radioligand therapies and ADCs.
We believe that pursuing underexplored targets with appropriate
drug modalities leads to transformative therapies. Our proprietary
memory B cell hybridoma technology allows for the rapid screening
and functional characterization of novel antibodies and
targets.
For more information, visit www.immunome.com or follow us on
Twitter and LinkedIn.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this communication regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities and
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995 (the “PSLRA”). We use words such as
“encourage,” “look forward,” “excitement,” potential,” “will,”
“plan,” “believe,” “goal,” “optimistic,” and similar expressions to
identify these forward-looking statements that are intended to be
covered by the safe-harbor provisions of the PSLRA. These
forward-looking statements include, but are not limited to,
statements regarding Immunome’s expectation that the purchase of
assets from Ayala will close; the clinical efficacy and potential
commercial success of the AL102 program; the expected benefits of
the Ayala transaction; and other statements regarding management’s
intentions, plans, beliefs, expectations or forecasts for the
future. No forward-looking statement can be guaranteed, and actual
results may differ materially from those projected. Such
forward-looking statements are based on Immunome’s expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including, but not limited to, the risk
that the transaction with Ayala will not be completed; potential
litigation relating to the proposed transaction that could be
instituted against Immunome, Ayala or their respective directors;
possible disruptions from the proposed transaction that could harm
Immunome’s and/or Ayala’s respective businesses; Immunome’s ability
to grow and successfully execute on its business plan, including
the development and commercialization of its pipeline; changes in
the applicable laws or regulations; the possibility that Immunome
may be adversely affected by other economic, business, and/or
competitive factors; the risk that regulatory approvals for
Immunome’s programs and product candidates are not obtained, are
delayed or are subject to unanticipated conditions; the risk that
pre-clinical data may not be predictive of clinical data; the risk
that interim results of a clinical trial do not necessarily predict
final results; potential delays in the commencement, enrollment and
completion of clinical trials and the reporting of data therefrom;
the complexity of numerous regulatory and legal requirements that
Immunome needs to comply with to operate its business; the reliance
on Immunome’s management; the prior experience and successes of the
Immunome’s management team not being indicative of any future
success; uncertainties related to Immunome’s capital requirements
and Immunome’s expected cash runway; the failure to obtain,
adequately protect, maintain or enforce Immunome’s intellectual
property rights; and other risks and uncertainties indicated from
time to time described in Immunome’s Annual Report on Form 10-K for
the year ended December 31, 2022 filed with Securities and Exchange
Commission (“SEC”) on March 16, 2023, Immunome’s Quarterly Report
on Form 10-Q for the quarter ended September 30, 2023 filed with
the SEC on November 9, 2023, and in Immunome’s other filings with
the SEC. Immunome cautions that the foregoing list of factors is
not exclusive and not to place undue reliance upon any
forward-looking statements which speak only as of the date made.
Moreover, Immunome operates in a very competitive and rapidly
changing environment. New risks emerge from time to time. Except as
required by law, Immunome does not undertake any obligation to
update publicly any forward-looking statements for any reason after
the date of this press release to conform these statements to
actual results or to changes in their expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240220647038/en/
Immunome Contact: Max Rosett Interim Chief Financial
Officer and EVP, Operations mrosett@immunome.com
Immunome (NASDAQ:IMNM)
過去 株価チャート
から 4 2024 まで 5 2024
Immunome (NASDAQ:IMNM)
過去 株価チャート
から 5 2023 まで 5 2024